Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$137.77 USD

137.77
2,784,193

+1.25 (0.92%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $138.00 +0.23 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for July 25th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 25th:

    Tracey Ryniec headshot

    5 Amazing Earnings Charts

    by Tracey Ryniec

    Will another beat push these 5 stocks to even greater heights?

      Zacks Equity Research

      Medical Product Earnings Lineup for Jul 25: TMO, BSX & More

      by Zacks Equity Research

      The Medical product market further gains momentum on the back of a recent two-year suspension of the controversial 2.3% Medical Device tax.

        Zacks Equity Research

        Quest Diagnostics (DGX) Q2 Earnings Meet, Guidance Narrowed

        by Zacks Equity Research

        Quest Diagnostics (DGX) gains on successful execution of its two-point strategy of accelerating growth and driving operational excellence in Q2.

          Zacks Equity Research

          Is a Surprise Coming for Align Technology (ALGN) This Earnings Season?

          by Zacks Equity Research

          Align Technology (ALGN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

            Zacks Equity Research

            Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance

            by Zacks Equity Research

            Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.

              Zacks Equity Research

              PetMed (PETS) Q1 Earnings Lag Estimates, Reorder Sales Solid

              by Zacks Equity Research

              We are encouraged by growth in PetMed's (PETS) reorder and new order sales in Q1. Increased online sales buoy optimism.

                Zacks Equity Research

                Can Overall Growth Drive ResMed's (RMD) Q4 Earnings?

                by Zacks Equity Research

                ResMed (RMD) is likely to keep its winning streak alive with a gain from strong performances on the domestic as well as global front in Q4.

                  Zacks Equity Research

                  Can CAG Growth Continue to Aid IDEXX (IDXX) in Q2 Earnings?

                  by Zacks Equity Research

                  IDEXX (IDXX) is enhancing its commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics.

                    Zacks Equity Research

                    Can Solid Overall Growth Drive Illumina's (ILMN) Q2 Earnings?

                    by Zacks Equity Research

                    Illumina (ILMN) to gain from strong revenues at the Product, Service and other segments in Q2.

                      Zacks Equity Research

                      Molecular Diagnostics to Aid Hologic's (HOLX) Q3 Earnings

                      by Zacks Equity Research

                      Strength in the Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) molecular diagnostics in Q3.

                        Zacks Equity Research

                        Top Ranked Momentum Stocks to Buy for July 23rd

                        by Zacks Equity Research

                        Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 23rd:

                          Zacks Equity Research

                          What's in Store for Universal Health's (UHS) Q2 Earnings?

                          by Zacks Equity Research

                          Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.

                            Zacks Equity Research

                            What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?

                            by Zacks Equity Research

                            HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.

                              Zacks Equity Research

                              What's in Store for GNC Holdings (GNC) This Earnings Season?

                              by Zacks Equity Research

                              GNC Holdings' (GNC) revenues are likely to decline on a year-over-year basis, owing to weakness in U.S. & Canada segments in Q2.

                                Zacks Equity Research

                                Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                                by Zacks Equity Research

                                We are upbeat about Abbott's (ABT) synergies from Alere buyout in the form of solid Rapid Diagnostics revenues. Emerging market performance has been promising.

                                  Zacks Equity Research

                                  Should iShares Morningstar Mid-Cap Growth ETF (JKH) Be on Your Investing Radar?

                                  by Zacks Equity Research

                                  Style Box ETF report for JKH

                                    Zacks Equity Research

                                    Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues

                                    by Zacks Equity Research

                                    Strong performance in the Instruments & Accessories as well as Systems segments drove Intuitive Surgical's (ISRG) top line in Q2.

                                      Zacks Equity Research

                                      Neogen (NEOG) Earnings and Revenues Beat Estimates in Q4

                                      by Zacks Equity Research

                                      Neogen (NEOG) sticks to its four-pronged growth strategy for steady progress. Also, the company's accretive buyouts and its broader international base are a boon.

                                        Zacks Equity Research

                                        Is a Beat in the Cards for Centene (CNC) in Q2 Earnings?

                                        by Zacks Equity Research

                                        Centene's (CNC) Q2 earnings is likely to gain from higher membership and revenues from Government business.

                                          Zacks Equity Research

                                          Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?

                                          by Zacks Equity Research

                                          Is (ALGN) Outperforming Other Medical Stocks This Year?

                                            Zacks Equity Research

                                            Has Align Technology (ALGN) Outpaced Other Medical Stocks This Year?

                                            by Zacks Equity Research

                                            Is (ALGN) Outperforming Other Medical Stocks This Year?

                                              Zacks Equity Research

                                              Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?

                                              by Zacks Equity Research

                                              Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.

                                                Zacks Equity Research

                                                Will Edwards' (EW) Steady Overall Growth Drive Q2 Earnings?

                                                by Zacks Equity Research

                                                Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q2.

                                                  Sweta Killa headshot

                                                  S&P 500 at 5-Month High: 5 Stocks Up More Than 45%

                                                  by Sweta Killa

                                                  Given that S&P 500 is at 5-month high, we have presented a bunch of stocks that have easily led the way on the index gaining more than 45% in the same time frame.